Current treatment options for craniofacial hyperhidrosis

Wolosker, Nelson; Faustino, Carolina Brito; Silva, Marcelo Fiorelli Alexandrino da; Campos, José Ribas Milanez de; Kauffman, Paulo

doi:10.1590/1677-5449.200152

Cited by 2 publications

(1 citation statement)

References 46 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 , 14 Antimuscarinic agents such as oxybutynin hydrochloride are also effective in the treatment of hyperhidrosis. 15 However, oxybutynin hydrochloride has not been approved by the Ministry of Food and Drug Safety for patients with hyperhidrosis. Intradermal BT and minimally invasive endoscopic sympathectomy were recently suggested as potential treatment methods.…”

Section: Discussionmentioning

confidence: 99%

Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report

Park

Kim

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Craniofacial hyperhidrosis causes sweating of the face and scalp due to excessive action of the sweat glands and manifests when patients become tense/nervous or develop an elevated body temperature. If noninvasive treatments are ineffective, invasive treatments such as a sympathetic block and resection are considered. A 32-year-old woman with no specific medical history was referred for uncontrolled craniofacial hyperhidrosis that included excessive sweating and hot flushing. Physical examination showed profuse sweating, and infrared thermography showed higher temperature in the neck and face than in the trunk. The patient underwent several stellate ganglion blocks, and her symptoms improved; however, the treatment effect was temporary. Botulinum toxin was then injected into the stellate ganglion. At the time of this writing, her sweating had been reduced for about 6 months and she was continuing to undergo follow-up. Craniofacial hyperhidrosis is a clinical condition in which patients experience excessive sweating of their faces and heads. It is less common than palmar and plantar hyperhidrosis. Botulinum toxin injection into the stellate ganglion is simple and safe and produces longer-lasting effects than other treatments, such as endoscopic sympathectomy and a single nerve block.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report

Park

Kim

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

show abstract

Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection

Prodan-Barbulescu,

Castiglione,

Burtic

et al. 2024

Toxins

View full text Add to dashboard Cite

Facial hyperhidrosis is a debilitating condition that can severely impact the quality of life. This study aimed to assess the long-term utility of Botulinum toxin type A therapy (BTA) for facial hyperhidrosis and its impact on quality of life over a one-year period. Conducted at the Pius Brinzeu Clinical Emergency Hospital in Timisoara, Romania, this longitudinal observational study involved 77 adult patients with primary facial hyperhidrosis. Participants received two sessions of Botulinum toxin injections (50 U IncoBTX-A each) and were evaluated at baseline, 6 months, and 12 months using the Hyperhidrosis Disease Severity Scale (HDSS), WHOQOL-BREF, Dermatology Life Quality Index (DLQI), and a bespoke survey. The study demonstrated significant reductions in HDSS scores from 3.6 ± 0.5 to 1.2 ± 0.8 post-treatment, sustained at 1.3 ± 0.6 at 12 months (p-value < 0.001). DLQI scores markedly decreased from 24.8 ± 4.2 to 6.2 ± 2.1 post-treatment, stabilizing at 6.5 ± 2.5 at 12 months (p-value < 0.001). Sweat production significantly dropped from 0.75 g ± 0.15 to 0.18 g ± 0.07 per 15 min (p-value < 0.001). WHOQOL-BREF scores improved notably in the mental domain from 66.7 ± 6.1 to 70.8 ± 5.2 at 12 months (p-value < 0.001), with physical and social domains also showing significant improvements. Correlation analysis revealed strong negative correlations between DLQI total score and HDSS (rho = −0.72, p-value < 0.001) and sweat production (rho = −0.68, p-value < 0.001). Regression analysis indicated significant predictors for DLQI total score, including HDSS (B Coefficient = −3.8, p-value < 0.001) and sweat production (B Coefficient = −2.2, p-value < 0.001). BTA therapy significantly improved the quality of life in facial hyperhidrosis patients, with lasting effects on symptom severity, sweat production, and quality of life domains. The correlation and regression analyses further substantiated the treatment’s impact on both physical and psychological aspects. These findings advocate Botulinum toxin as a viable long-term treatment for facial hyperhidrosis.

show abstract

Current treatment options for craniofacial hyperhidrosis

Cited by 2 publications

References 46 publications

Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report

Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report

Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection

Contact Info

Product

Resources

About